Kornimate/medical-research-clean huggingface dataset:
stress in pregnancy during the covid19 pandemic and impact on the newborn neurodevelopment

Conditions: Covid19 and Pregnancy

Summary: the covid19 pandemic, paradoxically, represents a valuable opportunity to carry out cohort studies that allow us to advance our knowledge about the relationship between inflammation, brain development and an increased risk of suffering from neuropsychiatric disorders or alterations. in addition, the current availability of sophisticated biological techniques and evaluation procedures represents an unique option for this purpose. here, we propose a cohort study of sars-cov-2 (type 2 coronavirus causing severe acute respiratory syndrome) infected pregnant women and newborns. we will try to answer the following questions: (i) what is the inflammatory / immune status of newborns (nbs) of mothers infected by covid19 like?; (ii) is there a relationship between the clinical characteristics of the maternal infection (severity / moment / of infection) and the inflammatory status of the newborn?; (iii) could these features increase the vulnerability to developing central nervous system (cns) alterations at an early age, and at some point during adult life ?; (iv) how is the covid19 infected mother's placenta altered? do the placental alterations covid19 mediated contribute to develop cns alterations?; (v) is the infection associated with phenotypes obtained through neurological and neurodevelopmental clinical evaluation (hypotonia, clumsiness, impaired communication and sociability) in children at 6 months and 12 months? our main objective is to explore how the presence of stressors and prenatal sars-cov-2 infection generates an abnormal inflammatory activity in the newborn, which is associated with neurodevelopmental disorders and which confers a greater risk of developing neuropsychiatric disorders. the biological information of the umbilical cord (fetus blood) and peripheral blood of the mother obtained after childbirth was provided by the cohort of women during the covid19 pandemic monitored during their pregnancy, delivery, childbirth and postpartum. these samples and the clinical characterisation of the cohort of mothers and newborns, of which we will be able to do an exhaustive longitudinal follow-up, are tremendously valuable at this time. there is a need to establish new research strategies to understand the pathophysiology of neuropsychiatric diseases, and to discover new molecular and cellular mechanisms involved in the development of the cns.


Eligibility criteria:
inclusion criteria: * 1. over 18 years old * 2. ultrasound-confirmed pregnancy * 3. infected (past or present) or non-infected with covid19 exclusion criteria: * 1. presents alcohol abuse during pregnancy * 2. other concomitant causes of risk of demonstrated neurodevelopmental disorders * 3. presents drug abuse except tobacco during pregnancy * 4. under 18 years of age
examination of cognitive function in obesity and following weight loss

Conditions: Obesity; Bariatric Surgery Candidate; Weight Loss

Summary: bariatric surgery is the most effective, long-term treatment for morbid obesity, and consistent with previous findings, individuals who lose significant weight after surgery also have improved cognition or "brain function". the mechanisms behind these cognitive improvements are currently unknown, but are the focus of much research effort. the goal of this pilot study is to thoroughly describe these changes in surgical versus medical weight loss patients over time in a repeated measures fashion.

recent studies have demonstrated that obesity is associated with decreased cognitive function and, interestingly, weight loss is associated with improved cognitive function. bariatric surgery is the most effective, long-term treatment for morbid obesity, and consistent with these previous findings, individuals who lose significant weight after surgery appear to have improved cognition. previous results have only reported the appearance of cognitive improvements starting at three months postoperatively, thus, the main focus of this study is to discover whether cognitive function improvements are seen as early as one month after bariatric surgery. an acceleration in the onset of cognitive function changes could provide insight towards the ambiguous underlying neural mechanisms. the benefits of bariatric surgery extend beyond reversible cognitive deficits. many of the medical comorbid conditions that these patients have before surgery (e.g. high blood pressure, high cholesterol, diabetes) typically resolve prior to any significant weight loss. the mechanisms for these weight-independent improvements are also undetermined. a secondary focus of this study is to determine whether or not cognitive function following bariatric surgery also improves prior to significant weight loss. to test whether cognitive function changes following bariatric surgery, two cohorts of surgical patients will be recruited as well as another group of patients undergoing medical weight loss treatment. the goal of this pilot study is to reproduce and expand upon previous findings that demonstrate cognitive improvements following bariatric surgery.

Eligibility criteria:
inclusion criteria: * english speaking * within the age rage of 18-70 years * able to give informed consent exclusion criteria: * neurological disorder or previous injury (e.g. stoke, dementia, seizures, traumatic brain injury) * history of any moderate to severe head injury (i.e. \>5 minutes of loss of consciousness) * history of severe psychiatric illness requiring current pharmacologic therapy(e.g. schizophrenia, bipolar disorder, personality disorders) * history of illicit drug or alcohol abuse * known diagnosis of learning or developmental disability * impaired sensory function * any prior suicide attempt * revisional bariatric surgery * current or former tobacco user / smoker * currently pregnant

Keywords: cognitive function obesity bariatric surgery metabolic surgery
polyuria associated with dexmedetomidine in operating room

Conditions: Polyuria

Summary: dexmedetomidine is an a2-adrenergic receptor agonist drug, widely used in intensive care for the sedation of patients on mechanical ventilation, as well as in the operating room during invasive procedures and during general anesthesia. it also has anti-inflammatory properties and reduces the need for opioids and benzodiazepines, which leads to a lower incidence of delirium associated with these drugs. among the frequent adverse effects associated with the administration of dexmedetomidine we can find bradycardia and hypotension, while some studies carried out in animals have shown that it can increase the diuretic rate. polyuria related to pharmacological agonism of a2-adrenergic receptors has been described in vitro and in studies performed in animal models, and is believed to be the result of functional antagonism of arginine vasopressin. despite its widespread use as a sedative and adjunctive anesthetic, there are very few reports in the literature of dexmedetomidine-related polyuria in humans. currently there are no reports in the literature on the incidence of polyuria induced by the intraoperative administration of dexmedetomidine.

this is a prospective, observational study designed to determine the incidence of polyuria, defined as urine output greater than 150 ml/h or 3 ml/kg/h, associated with the administration of dexmedetomidine during the intraoperative period. the investigators will prospectively and consecutively study all patients scheduled for high complexity surgery under general anesthesia for a period of 4 months. the diuretic rate will be quantified in ml/hour. a urine sample will be taken two hours after the start of surgery to assess sodium and urinary density, and an arterial blood sample will be taken to determine serum sodium. hydration will be recorded in milliliters per hour, detailing the type of solution used. all data obtained will be captured in a redcap data collection form.

Eligibility criteria:
inclusion criteria: * age \> 18 years old * scheduled surgery * dexmedetomidine in boluses and/or continuous infusion during intra-operative period * patients who require arterial line and urinary catheter exclusion criteria: * chronic renal disease. * egfr \< 60 ml/min/1.73m2 for more than 3 months of evolution. * emergency or unscheduled surgeries. * central nervous system disease at the sellar or suprasellar level. * patients receiving diuretics. * liver cirrhosis. * adrenal gland disease.

Keywords: dexmedetomidine polyuria anesthesia
fibrolamellar carcinoma: an international registry study

Conditions: Fibrolamellar Cancer of the Liver

Summary: fibrolamellar hepatocellular carcinoma (flc) is a rare (0.05 per 100,000) subtype of primary liver cancer which predominantly affects younger patients, median age of diagnosis 22-23 years. in patients with advanced stage disease the prognosis is poor, and even with aggressive surgery the 5 year survival is less than 50%. due to the very low incidence of flc clinical trials are limited, and as these patients are excluded from most clinical trials there is a lack of consensus on the optimal systemic therapy to employ in this population group. there are a number of chemotherapy compounds that have been investigated although these are single-institutional case series and/or registry-based studies. the majority of published registry studies are based in the united states hence it is important to describe the patterns of treatment in europe which has different regulatory approvals for access to therapeutics. our aim is to run a european multisite registry study detailing the clinical course of \>100 patients with flc that have received systemic therapy.


Eligibility criteria:
inclusion criteria: * histologic confirmed diagnosis of flc * written informed consent will be required for the prospective cohort * adults of \>18 years of age exclusion criteria: * any non- histologic confirmed diagnosis of flc * participants with insufficient clinical/ follow up data
the effectiveness of a health promotion program for older people with post-covid-19 sarcopenia

Conditions: Post COVID-19 Condition

Summary: the goal of this clinical trial is to investigate the prevalence of sarcopenia in older people with post-covid-19 living in ratchatewi district, bangkok and to test the effectiveness of health promotion program for older people with post-covid-19 sarcopenia. the main questions it aim to answer are: • how many is the prevalence of sarcopenia in older people with post-covid-19 living in ratchatewi district, bangkok? • can the health promotion program improve muscle mass and muscle strength in older people with post-covid-19 sarcopenia ? participants will be asked eating protein supplement one scoop /day and exercising 2 times/week for 3 months.


Eligibility criteria:
inclusion criteria: * older people with post-covid-19 sarcopenia aged more than and equal 60 years * no disabilities * able to read, write and communicate thai langue * live in bangkok * moderate post-covid-19 state defined by thai version of the covid-19 yorkshire rehabilitation scale * no soy protein allergy * sign inform consent exclusion criteria: * severe post-covid-19 state defined by thai version of the covid-19 yorkshire rehabilitation scale and complicated health problems * disabilities * unable to read, write and communicate thai langue * soy protein allergy * ckd 4 and ckd 5 * deny or withdraw from project

Keywords: sarcopenia older people health promotion program post covid-19
oral feeding delay prevention in preterm newborns

Conditions: Preventive Care

Summary: preventing oral feeding delays in preterm newborns remains a stake for nicu nowadays. indeed, it lengthens hospitalization duration, distorts parent-newborns relationships, and increases the risks of adverse nursing outcomes. does a routine individualized developmental preventive feeding care implying parents favors earlier autonomous oral feeding achievement in preterm newborns as compared with a standardized routine program of orofacial stimulations, despite neonatal risks that every preterm newborn cumulates during hospitalization stay ?

the goal of this observational study is to compare the efficiency of two routine preventive feeding care in preterm newborns, taking into account neonatal cumulated risks for each preterm newborn participant. the main question it aims to answer is: does a prospective individualized routine developmental preventive feeding care leads to earlier oral feeding achievement in preterm newborns despite individual risks, as compared with a retrospective standardized routine program. the group of preterm newborns prospectively assigned in the study will be included in nidcap strengthen with a parental support on nursing care named parentalim. the group of preterm newborns retrospectively assigned in the study received orofacial stimulations in a standardized protocol way (sofs) researchers will compare prospective and retrospective groups to see if the prospective group achieve autonomous oral feeding, despite individual neonatal cumulated risks, significantly earlier than retrospective group.

Eligibility criteria:
inclusion criteria: * parents of preterm newborns born before 34 weeks of amenorrhea * parents who agree participating in the study after signing an informed consent. * minimal delay of 72 hours and maximal delay of 15 days after birth to inform parents and wait their consent. exclusion criteria: * parents of preterm newborns born after 35 weeks of amenorrhea * parents who disagree participating in the study, even after signing the informed consent. * parents of preterm newborns born with cerebral, maxillo-facial, digestive, cardiac, genetic or syndromic abnormalities.

Keywords: preterm newborns individualized developmental care parental suppport for nursing orofacial stimulations oral feeding
s086 tablets for chronic heart failure with reduced ejection fraction

Conditions: Chronic Heart Failure With Reduced Ejection Fraction

Summary: a randomized, double-blind, positive-drug parallel controlled, multicenter phase iii trial of the efficacy and safety of s086 tablets in patients with chronic heart failure with reduced ejection fraction (hfref)


Eligibility criteria:
inclusion criteria: 1. patients with chronic heart failure (nyha grade ⅱ-ⅳ) with reduced ejection fraction (lvef≤40%) and elevated bnp were diagnosed 1a. 2. patients received a stable dose of the underlying treatment for heart failure, defined as no change in dose for at least 4 weeks before screening 1b. 3. volunteer to participate in the trial and sign an informed consent form 1c. exclusion criteria: 1. previous continuous administration of sacubitril valsartan sodium 150mg bid or more for more than 3 months 1a. 2. use of other study drugs or use of any study medical device within 1 day of the visit or within 30 days prior to the visit or within 5 half-lives of the drug, whichever is longer 1b. 3. known or suspected allergy to s086, sacubitril valsartan sodium, arb, acei, or enkephin inhibitor (nepi), and known or suspected contraindications to sacubitril valsartan sodium 1c. 4. a previous history of intolerance to the recommended target dose of acei or arb 1d. 5. he had a history of angioedema 1e. 6. acute coronary syndrome occurred within 6 weeks before visit 1 1f.
activity limitations in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: objective: to evaluate what factors contribute to activity limitations in subjects with rheumatoid arthritis considering the international classification of functioning, disability and health model. methods: a cross-sectional study on 81 individuals with rheumatoid arthritis (ra) using instruments to measure five constructs of the component activities.

the investigators used the icf model to analyze factors reported to be associated with functioning and disability in individuals with ra, including dexterity fatigue, stiffness , pinch, handgrip, strength, range of motion (rom) deficit, deformities , mental health, vitality, and pain .

Eligibility criteria:
inclusion criteria: * age over 18 years, * clinical diagnosis rheumatic arthritis * mental competence by the mini-mental state examination exclusion criteria:- * had undergone upper limb surgery, * had an uncorrected visual deficit that could compromise functionality

Keywords: human activity international classification of functioning
ataxia gaa-fgf14 - descriptive genetic and clinical study

Conditions: Ataxia, Gait

Summary: cerebellar ataxias of late onset are of undetermined etiology in many cases. a new cause of late-onset cerebellar ataxia was discovered in january 2023 corresponding to an expansion of gaa triplets in intron 1 of the fgf14 gene. however, this cerebellar ataxia is still poorly known and requires further investigations to know its clinical phenotype and its evolution in order to propose a diagnosis and a genetic counseling adapted to patients and families. the objective of our study will be to describe the clinical and genotypic phenotype of patients with gaa-fgf14

the objective of our study will be to describe the clinical and genotypic phenotype of patients with gaa-fgf14. we wish to describe the precise clinical phenotype by detailing each patient's clinical examination, medical history, treatment history, frequency and symptomatology of episodes, mri radiological data, otho-rihno-laryngeal examination data etc . we would also like to describe the precise genotype for each patient, specifying the number of gaa expansions and its characteristics.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of cerebellar ataxia of type gaa-fgf14 exclusion criteria: * patients not wishing to be followed

Keywords: ataxia spinocerebellar ataxia genetic ataxia
prevalence of unknown and known diabetes in patients with frozen shoulder

Conditions: Diabetes Mellitus; Frozen Shoulder

Summary: the purpose of the study is to investigate how high the prevalence of diabetes (known and unknown) is among patients with a frozen shoulder. our hypothesis is that it is around 30-40 %. another purpose is to investigate whether patients with diabetes have a worse and more painful frozen shoulder than patients without diabetes, and whether the diabetes have an influence on the prognosis.

patients who are not diagnosed with diabetes would be ask to give a blood sample to investigate if they have an unknown diabetes. all patients with frozen shoulder will be asked to fill out a questionnaire (oxford shoulder score) to clarify how bad their frozen shoulder is. all patients will receive the questionnaire 6 and 24 month following the date on inclusion.

Eligibility criteria:
inclusion criteria: all newly referred patients who is being diagnosed with frozen shoulder - exclusion criteria: age below 25 or above 75, pt. who don't read or understand danish, not danish citizen, patients with mental illness, pt. with a abuse of alcohol or substances, pregnancy, pt. who within 4 months have been injected with adrenocortical hormone, arthrosis in the glenohumeral joint, avascular necrosis of caput humeri, rotator cuff lesion. -

Keywords: diabetes mellitus frozen shoulder adhesive capsulitis
associated genes with atomoxetine response in attention deficit hyperactivity disorder (adhd)

Conditions: Attention Deficit Hyperactivity Disorder

Summary: attention deficit hyperactivity disorder (adhd) is the most common behavior disorder, with the prevalence of 3% to 6% in children and adolescents. the patients' academic achievements, professions and social livings are impaired. comorbid antisocial behavior, substance abuse and delinquency burden family and society. stimulants used to be the first line drug. but the medication compliance is poor because of strict drug administration. atomoxetine is a new non-stimulant drug, which can effectively improve adhd symptoms. but it achieves effect slowly, the drug responses differ significantly, and side effects interfere compliance. since genetic factors is the most important cause for different drug responses, this project studies candidate genes potentially associated with atomoxetine medication, with the aim to find 2 to 3 gene polymorphisms influencing the drug response of adhd. the study adopts cohort design. a sample of more than 100 adhd cases with atomoxetine medication is to be collected. the rapid genotyping of large sample depends on high-through laboratory. new statistic method is to be used to improve the sensitivity of the target gene detection. there has been no such report in country and overseas. this project will provide basic information for forecasting drug response, improving clinical effects, tolerance and long-term compliance.


Eligibility criteria:
inclusion criteria: * the subject should meet with the dsm-iv adhd criteria, confirmed by semi-structured interview. * the subject has not accepted any treatment for adhd before, or he/she received methylphenidate or atomoxetine treatment but has stopped for 1 or 4 weeks respectively. * han chinese * parent sign the informed consent exclusion criteria: * who are allergy to atomoxetine * who can not complete the titration procedure because of untolerable of the side effect * who combined other psychotropic drugs or non-drug intervention for adhd. * children who can not be compliant with the blood withdraw.